Home > Insider Trading > Filing (0001725160-21-000200)

Filing Details

Accession Number:: 0001725160-21-000200
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-10-04 21:16:57
Reporting Period:: 2021-10-01

Accepted Time:: 2021-10-04 21:16:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1725160	Zentalis Pharmaceuticals Inc.	ZNTL	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1807484	D. Kevin Bunker	C/O Zentalis Pharmaceuticals, Inc. 530 Seventh Avenue, Suite 2201 New York NY 10018	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-09-24	350	$0.00	995,067	No	5	G	Direct
Common Stock	Acquisiton	2021-09-24	350	$0.00	350	No	5	G	Indirect	As UTMA custodian for sons
Common Stock	Disposition	2021-10-01	1,416	$64.73	7,004	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-10-01	3,121	$65.80	3,883	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-10-01	3,679	$66.89	204	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-10-01	204	$67.44	0	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	5	G	Direct
No	5	G	Indirect	As UTMA custodian for sons
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

Transfer to Reporting Person in his capacity as custodian for sons under Uniform Transfers to Minors Act. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any.
Includes 576 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on September 30, 2021.
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $64.26 to $65.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $65.29 to $66.27. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $66.41 to $67.34. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $67.44 to $67.45. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.